Dersimelagon Beneficial for Erythropoietic, X-Linked Protoporphyria; Dersimelagon at doses of 100 and 300 mg increases duration of symptom-free sunlight exposure versus placebo.

Press/Media

Period	13 Apr 2023

Media coverage

Title	Dersimelagon Beneficial for Erythropoietic, X-Linked Protoporphyria; Dersimelagon at doses of 100 and 300 mg increases duration of symptom-free sunlight exposure versus placebo.
Media name/outlet	Physician's Briefings
Country/Territory	United States
Date	13/04/23
URL	metabase.moreover.com/noarticleurl?type=psh&lni=6816-1VT1-JCBJ-K2V6-00000-00
Persons	Manisha Balwani